Aclaris Therapeutics, Inc.·4

Feb 3, 5:36 PM ET

Balthaser Kevin 4

4 · Aclaris Therapeutics, Inc. · Filed Feb 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Aclaris (ACRS) CFO Kevin Balthaser Receives RSUs; Shares Withheld for Taxes

What Happened
Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics (ACRS), had restricted stock units (RSUs) convert into 14,750 shares on Feb 1, 2026. To satisfy tax withholding obligations related to the vesting/settlement, the issuer withheld 4,984 of those shares at $3.51 per share, yielding approximately $17,494. This was a settlement of an award, not an open-market sale or purchase.

Key Details

  • Transaction date: 2026-02-01; Form 4 filed 2026-02-03.
  • Conversion/settlement: 14,750 shares acquired via conversion of RSUs (derivative code M).
  • Tax withholding: 4,984 shares withheld (code F) at $3.51/share for ~$17,494.
  • Reported disposition of derivative: an entry shows 14,750 shares with $0 per share (derivative conversion/settlement).
  • Shares owned after the transaction: not specified in the provided filing details.
  • Footnotes:
    • F1: Each RSU represents a contingent right to one share.
    • F2: Withholding of shares by the issuer to satisfy tax withholding upon vesting/settlement.
    • F3: RSUs vest in four equal installments on the first through fourth anniversaries of Feb 1, 2024, subject to continuous service.

Context
This was a routine equity award settlement and a tax-withholding action (often called a cashless/stock withholding), not an open-market sale or purchase. Such withholding transactions are common when RSUs vest and do not necessarily indicate the insider’s view on the company’s stock.

Insider Transaction Report

Form 4
Period: 2026-02-01
Balthaser Kevin
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-01+14,750175,163 total
  • Tax Payment

    Common Stock

    [F2]
    2026-02-01$3.51/sh4,984$17,494170,179 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F3]
    2026-02-0114,75029,500 total
    Common Stock (14,750 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
  • [F3]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
Signature
/s/ Matthew Rothman, Attorney-in-Fact|2026-02-03

Documents

1 file
  • 4
    form4-02032026_100245.xmlPrimary